Management of Lymph Node-positive Penile Cancer: A Systematic Review.

Chemoradiotherapy Chemotherapy Inguinal lymph-node dissection Lymph-node management Management Multimodal therapy Penile cancer Radiotherapy

Journal

European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719

Informations de publication

Date de publication:
17 May 2023
Historique:
received: 20 11 2022
revised: 27 03 2023
accepted: 19 04 2023
medline: 20 5 2023
pubmed: 20 5 2023
entrez: 19 5 2023
Statut: aheadofprint

Résumé

Lymph node (LN) involvement in penile cancer is associated with poor survival. Early diagnosis and management significantly impact survival, with multimodal treatment approaches often considered in advanced disease. To assess the clinical effectiveness of treatment options available for the management of inguinal and pelvic lymphadenopathy in men with penile cancer. EMBASE, MEDLINE, the Cochrane Database of Systematic Reviews, and other databases were searched from 1990 to July 2022. Randomised controlled trials (RCTs), nonrandomised comparative studies (NRCSs), and case series (CSs) were included. We identified 107 studies, involving 9582 patients from two RCTs, 28 NRCSs, and 77 CSs. The quality of evidence is considered poor. Surgery is the mainstay of LN disease management, with early inguinal LN dissection (ILND) associated with better outcomes. Videoendoscopic ILND may offer comparable survival outcomes to open ILND with lower wound-related morbidity. Ipsilateral pelvic LN dissection (PLND) in N2-3 cases improves overall survival in comparison to no pelvic surgery. Neoadjuvant chemotherapy in N2-3 disease showed a pathological complete response rate of 13% and an objective response rate of 51%. Adjuvant radiotherapy may benefit pN2-3 but not pN1 disease. Adjuvant chemoradiotherapy may provide a small survival benefit in N3 disease. Adjuvant radiotherapy and chemotherapy improve outcomes after PLND for pelvic LN metastases. Early LND improves survival in nodal disease in penile cancer. Multimodal treatments may provide additional benefit in pN2-3 cases; however, data are limited. Therefore, individualised management of patients with nodal disease should be discussed in a multidisciplinary team setting. Spread of penile cancer to the lymph nodes is best managed with surgery, which improves survival and has curative potential. Supplementary treatment, including the use of chemotherapy and/or radiotherapy, may further improve survival in advanced disease. Patients with penile cancer with lymph node involvement should be treated by a multidisciplinary team.

Identifiants

pubmed: 37208237
pii: S0302-2838(23)02779-3
doi: 10.1016/j.eururo.2023.04.018
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Ashwin Sachdeva (A)

Division of Cancer Sciences, University of Manchester, Manchester, UK; Department of Urology, The Christie NHS Foundation Trust, Manchester, UK. Electronic address: ashwin.sachdeva@manchester.ac.uk.

Luke McGuinness (L)

Department of Urology, South Tyneside and Sunderland NHS Foundation Trust, Sunderland, UK.

Łukasz Zapala (Ł)

Department of Urology, Medical University of Warsaw, Warsaw, Poland.

Isabella Greco (I)

Department of Urological Minimally Invasive and Robotic Surgery and Kidney Transplantation, Careggi Hospital, University of Florence, Florence, Italy.

Herney Andres Garcia-Perdomo (HA)

Division of Urology/Uro-oncology, Department of Surgery, School of Medicine, Universidad Del Valle, Cali, Colombia.

Mithun Kailavasan (M)

Nottingham City Hospital, Nottingham, UK.

Tiago Antunes-Lopes (T)

Department of Urology, Hospital de S. João, Porto, Portugal.

Benjamin Ayres (B)

Department of Urology, St. George's University Hospitals NHS Foundation Trust, London, UK.

Lenka Barreto (L)

Department of Urology, University Hospital Nitra, Nitra, Slovakia.

Riccardo Campi (R)

Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi University Hospital, Florence, Italy.

Juanita Crook (J)

British Columbia Cancer Agency, University of British Columbia, Kelowna, Canada.

Peter Johnstone (P)

Departments of Radiation Oncology and Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA.

Vivek Kumar (V)

Department of Urology, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK.

Kenneth Manzie (K)

Patient Advocate, ORCHID, UK.

Jack David Marcus (JD)

Multicancer Fighter Patient Advocate, Us TOO, New York, NY, USA.

Andrea Necchi (A)

Department of Urology and Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Pedro Oliveira (P)

Department of Pathology, The Christie NHS Foundation Trust, Manchester, UK; Centre for the Research and Technology of Agro-Environmental and Biological Sciences, University of Trásos-Montes and Alto Douro, Vila Real, Portugal; Veterinary Sciences Department, University of Trásos-Montes and Alto Douro, Vila Real, Portugal.

John Osborne (J)

Patient Advocate, ORCHID, UK.

Lance C Pagliaro (LC)

Department of Oncology, Mayo Clinic, Rochester, MN, USA.

Chris Protzel (C)

Helios Clinics Schwerin, Schwerin, Germany.

R Bryan Rumble (R)

American Society of Clinical Oncology, Alexandria, VA, USA.

Diego F Sánchez Martínez (DF)

Facultad de Ciencias Medicas, Universidad Nacional de Asuncion, Asuncion, Paraguay.

Philippe E Spiess (PE)

Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

Scott T Tagawa (ST)

Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY, USA.

Michiel S van der Heijden (MS)

Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Arie S Parnham (AS)

Department of Urology, The Christie NHS Foundation Trust, Manchester, UK.

Curtis A Pettaway (CA)

The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Maarten Albersen (M)

Department of Urology, University Hospitals Leuven, Leuven, Belgium.

Vijay K Sangar (VK)

Division of Cancer Sciences, University of Manchester, Manchester, UK; Department of Urology, The Christie NHS Foundation Trust, Manchester, UK.

Oscar R Brouwer (OR)

The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

Vasileios I Sakalis (VI)

Hippokrateion General Hospital of Thessaloniki, Greece.

Classifications MeSH